AC
GBT

Apogem Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Apogem Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,609
Closed -$243K – 175
2022
Q2 		$243K Buy
+7,609
New +$223K 0.22% 127

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Apogem Capital's GBT Position: Q3 2022 in Review

Apogem Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 7,609 shares — an estimated $243K sold.

Apogem Capital first reported a position in GBT in Q2 2022 and held it in 1 quarter. The position peaked at $243K in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Apogem Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Apogem Capital sold 7,609 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $243K.
  • Apogem Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2022 and held it in 1 quarter.
  • Apogem Capital's Global Blood Therapeutics, Inc. position peaked at $243K in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Apogem Capital's 13F filing for Q3 2022, filed 14 Nov 2022.